Mary Fidler to Humans
This is a "connection" page, showing publications Mary Fidler has written about Humans.
Connection Strength
0.586
-
Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer. Ann Surg Oncol. 2019 Nov; 26(12):3807-3808.
Score: 0.036
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.033
-
Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
Score: 0.030
-
Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
Score: 0.025
-
Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
Score: 0.025
-
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
Score: 0.022
-
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
Score: 0.021
-
Treatment of locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol. 2009 Jul; 7(7):455-64, 479-80.
Score: 0.018
-
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
Score: 0.016
-
Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy. J Cachexia Sarcopenia Muscle. 2024 Dec; 15(6):2311-2322.
Score: 0.013
-
A nationwide analysis of salvage surgery for laryngeal cancer in the elderly. Head Neck. 2023 11; 45(11):2915-2924.
Score: 0.012
-
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 09; 18(9):1209-1221.
Score: 0.012
-
Unusual vasovagal-type autonomic dysfunction secondary to immune checkpoint inhibitor therapy. BMJ Case Rep. 2023 Feb 20; 16(2).
Score: 0.011
-
Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies. Anticancer Res. 2022 Nov; 42(11):5449-5455.
Score: 0.011
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
Score: 0.011
-
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674.
Score: 0.011
-
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.
Score: 0.010
-
In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. J Am Soc Nephrol. 2021 03; 32(3):695-706.
Score: 0.010
-
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
Score: 0.010
-
De novo pauci-immune glomerulonephritis in renal allografts. Mod Pathol. 2020 03; 33(3):440-447.
Score: 0.009
-
The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney Int. 2019 10; 96(4):1005-1009.
Score: 0.009
-
Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer. Am J Otolaryngol. 2019 Sep - Oct; 40(5):626-630.
Score: 0.009
-
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019 05; 14(5):793-801.
Score: 0.009
-
Clinical features and outcomes in young adults with oral tongue cancer. Am J Otolaryngol. 2019 Jan - Feb; 40(1):93-96.
Score: 0.008
-
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399.
Score: 0.008
-
Congophilic Fibrillary Glomerulonephritis: A Case Series. Am J Kidney Dis. 2018 09; 72(3):325-336.
Score: 0.008
-
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 2018 07; 94(1):159-169.
Score: 0.008
-
National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma. Cancer. 2017 01 01; 123(2):273-282.
Score: 0.007
-
Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. Oral Oncol. 2016 Mar; 54:58-67.
Score: 0.007
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 09; 387(10027):1540-1550.
Score: 0.007
-
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
Score: 0.007
-
Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):512-22.
Score: 0.007
-
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
Score: 0.007
-
Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int. 2015 Oct; 88(4):867-73.
Score: 0.007
-
Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
Score: 0.007
-
Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
Score: 0.007
-
Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
Score: 0.007
-
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015 Jan 10; 33(2):189-94.
Score: 0.006
-
Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015 Feb; 87(2):458-64.
Score: 0.006
-
Biopsy-proven acute interstitial nephritis, 1993-2011: a?case?series. Am J Kidney Dis. 2014 Oct; 64(4):558-66.
Score: 0.006
-
Membranous nephropathy with crescents: a series of 19 cases. Am J Kidney Dis. 2014 Jul; 64(1):66-73.
Score: 0.006
-
Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing. Oral Oncol. 2014 May; 50(5):520-6.
Score: 0.006
-
Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014 Aug; 86(2):370-7.
Score: 0.006
-
Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
Score: 0.006
-
Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
Score: 0.006
-
Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant. 2012 Nov; 27(11):4137-46.
Score: 0.006
-
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012 Jul; 82(2):226-34.
Score: 0.005
-
Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012 Jun; 59(6):786-94.
Score: 0.005
-
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012 Feb; 7(2):231-9.
Score: 0.005
-
Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012 Mar; 27(3):1097-101.
Score: 0.005
-
Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012 May; 23(5):1095-1103.
Score: 0.005
-
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011 Oct; 80(7):753-9.
Score: 0.005
-
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
Score: 0.005
-
Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
Score: 0.005
-
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
Score: 0.005
-
Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
Score: 0.005
-
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
Score: 0.005
-
A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation. 2005 Dec 15; 80(11):1572-7.
Score: 0.003